Who are Cannabidiol oral oil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cesamet, Marinol, Cesamet™ (nabilone), Cannabidiol Oral Solution [Epidiolex], CBD, Cannabis Sativa Oil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cannabidiol-oral-oil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cannabidiol oral oil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cannabidiol oral oil (Cannabidiol oral oil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology/Psychiatry.

marketed Cannabinoid Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors) Neurology/Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Cannabidiol oral oil (Cannabidiol oral oil) — Hôpital le Vinatier. Cannabidiol modulates endocannabinoid signaling and multiple other pathways to produce anxiolytic, anti-inflammatory, and neuroprotective effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cannabidiol oral oil TARGET	Cannabidiol oral oil	Hôpital le Vinatier	marketed	Cannabinoid	Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors)
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
Marinol	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Cannabidiol Oral Solution [Epidiolex]	Cannabidiol Oral Solution [Epidiolex]	Silkiss Eye Surgery	marketed	Cannabinoid anticonvulsant	TRP channels, adenosine signaling, serotonin receptors (multi-target)
CBD	CBD	Stero Biotechs Ltd.	marketed	Cannabinoid	5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric)
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

Wayne State University · 3 drugs in this class
Hôpital le Vinatier · 1 drug in this class
Montefiore Medical Center · 1 drug in this class
OMNI Medical Services, LLC · 1 drug in this class
Gold Coast Hospital and Health Service · 1 drug in this class
Stero Biotechs Ltd. · 1 drug in this class
University of California, San Diego · 1 drug in this class
University of Connecticut · 1 drug in this class
Staci Gruber, Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cannabidiol oral oil — Competitive Intelligence Brief. https://druglandscape.com/ci/cannabidiol-oral-oil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab